IGF-1 (Insulin-like Growth Factor 1), also known as Somatomedin C, is a peptide hormone that has rapidly gained prominence since the mid-2000s and, as of 2024, is extensively utilized in the realms of bodybuilding and performance enhancement.
Olympia champion Dorian Yates is credited as the first to use IGF-1 for performance enhancement in the early 1990s. At the time, it was an extremely rare and expensive compound, but it subsequently spread rapidly among professional bodybuilders.
IGF-1 is not an anabolic steroid but a polypeptide-based protein hormone, structurally very similar to insulin. It is primarily produced endogenously in the liver, and its secretion is stimulated by human growth hormone (HGH).
In other words, HGH is a precursor hormone that induces the production of IGF-1, and most of HGH’s anabolic effects are mediated through IGF-1.
Like insulin, IGF-1 functions as a nutrient shuttle, but it is more selective in its mechanism of action and target tissues.
IGF-1 specifically shuttles amino acids and glucose into muscle cells, where these nutrients are directly utilized for the synthesis of new muscle tissue.
Furthermore, IGF-1 exerts potent anabolic effects not only in muscle but also in various other tissues, including bone, connective tissue, and internal organs.
In contrast, insulin distributes nutrients throughout the entire body more broadly and has lower tissue selectivity than IGF-1.
The physiological role of IGF-1 varies with developmental stage; it plays a crucial role in regulating growth during childhood and induces anabolic actions specialized for muscle growth and recovery in adulthood.
In a medical context, it is primarily used to treat growth disorders, and its potential applications are currently being researched in areas such as dwarfism, anti-aging, neurological diseases, cancer, and stroke.
As a relatively recent discovery in the medical field, IGF-1’s clinical applications are gradually expanding, and it is being actively studied as an experimental therapeutic agent.
Currently, various IGF-1 derivatives have been developed for exogenous administration, with the most prominent being IGF-1, IGF-1 LR3, and IGF-1 DES.
Each of these variants possesses distinct characteristics regarding biological half-life, tissue selectivity, and duration of action, and they are incorporated into protocols based on specific goals and strategies.
Online information regarding IGF-1 is often mixed and inaccurate, making clear, scientific guidance essential for elite bodybuilders encountering this compound for the first time.
This document will hereafter delve deeper into the specific characteristics and strategic applications of each derivative.
Chemical Profile and Properties of IGF-1
IGF-1 is a polypeptide hormone composed of a 70-amino acid chain, giving it a longer and more complex structure than insulin’s 51-amino acid chain.
While insulin exhibits potent anabolic effects and specific nutrient-shuttling functions in muscle tissue, and also induces anabolic responses in organs, connective tissues, and the skeletal system, IGF-1 displays a more specialized anabolic pattern.
IGF-1 is endogenously produced in the liver, a process driven entirely by HGH.
Therefore, no matter how high the dose of HGH administered, there is a limit dictated by the liver’s capacity to produce IGF-1. To overcome this ceiling, exogenous IGF-1 is strategically introduced.
This approach bypasses the HGH-dependent hepatic production system to induce the anabolic effects of IGF-1 more directly and efficiently.
IGF-1 does more than just transport amino acids and glucose into muscle cells; it possesses the rare ability to promote muscle cell hyperplasia—the creation and differentiation of entirely new muscle cells—rather than just hypertrophy, which is the growth in size of existing muscle cells.
However, it is crucial to understand a key biochemical distinction related to IGF-1’s bioactivity.
Approximately 99% of the IGF-1 in the bloodstream is bound by specialized proteins called IGFBPs (Insulin-like Growth Factor Binding Proteins). It is the small fraction of unbound, or ‘free form,’ IGF-1 that is actually active and responsible for muscle cell proliferation.
To overcome this binding limitation, pharmaceutical research has led to the development of modified versions of IGF-1, structurally altered to resist binding to IGFBPs. This has resulted in variants like IGF-1 LR3 and IGF-1 DES.
These structural modifications significantly impact IGF-1’s bioavailability, duration of action, and tissue selectivity, allowing them to be tailored to specific cycle strategies.
Furthermore, a key physiological characteristic of IGF-1 is that it circulates systemically and exerts a whole-body anabolic effect, regardless of the injection site.
In other words, injecting it locally into a specific area does not induce muscle growth solely in that spot, a common misconception for users expecting site-specific enhancement.
Regardless of the variant, IGF-1 follows a systemic mechanism of action, a critical factor that must be accurately considered when designing a protocol.
IGF-1 Variants (IGF-1 LR3, IGF-1 DES)
IGF-1 is available in two primary modified forms. It is essential to recognize that regardless of the variant, it acts systemically throughout the body after administration and does not induce a measurable level of localized growth, even when injected directly into a muscle.
IGF-1 LR3 is currently the most widely used variant and is generally favored by bodybuilders and athletes. It is created by adding a 13-amino acid extension to the N-terminus of the original 70-amino acid bioidentical IGF-1, resulting in a total structure of 83 amino acids.
Additionally, another structural modification involves substituting arginine for glutamic acid at the third position. This combination of alterations allows IGF-1 LR3 to maintain a strong binding affinity for the IGF-1 receptor while significantly reducing its affinity for IGFBPs (IGF Binding Proteins).
This modification extends IGF-1’s intrinsic half-life from 12-15 hours to 20-30 hours and increases its biological potency to approximately three times that of bioidentical IGF-1.
IGF-1 DES (1-3) is a highly potent, short-acting variant of IGF-1. It is composed of a 67-amino acid chain, created by removing the first three amino acids from the N-terminus of bioidentical IGF-1.
This structural deletion further reduces its binding affinity to IGFBPs, resulting in a potency and strength approximately 10 times greater than bioidentical IGF-1 and 5 times greater than IGF-1 LR3.
However, its half-life is only 20-30 minutes, making it strategically applicable when immediate action is required post-administration. Due to its intense activity, some reports have suggested the possibility of localized muscle growth at the injection site.
Nonetheless, as numerous studies and case reports have shown, once IGF-1 DES enters the bloodstream, it ultimately follows a systemic mechanism. Therefore, long-term strategies and contest prep protocols must be designed with this systemic action in mind.
IGF-1 Side Effects
The side effects of IGF-1 are well-documented through extensive medical literature, research, and feedback from countless bodybuilders and athletes who have used it. While it is relatively well-tolerated by most users, it must be clearly understood that, like all hormonal agents, IGF-1 carries undeniable potential risks and side effects.
The side effects of IGF-1 often manifest as long-term issues associated with prolonged use and high dosages. In the short term, the most commonly reported side effect is hypoglycemia.
Similar to insulin, IGF-1 facilitates the rapid uptake of glucose into muscle and other cells, which can cause a sharp drop in plasma blood sugar levels. Although this occurs less frequently than with insulin, it remains a potential hypoglycemic risk.
Users with diabetes or a family history of the condition must be particularly cautious of this hypoglycemic risk. While using IGF-1, it is imperative to continuously monitor blood glucose levels, recognize the early signs of hypoglycemia, and adjust one’s diet accordingly.
As a growth factor physiologically linked to growth hormone, IGF-1 can potentially accelerate tumor growth in individuals with active cancer or a history of cancer.
While IGF-1 does not directly cause cancer, it can amplify the growth signals of pre-existing abnormal cells. Therefore, its use should be strictly limited or prohibited for such individuals.
It is also important to approach IGF-1 with the understanding that it is not inherently negative, as it plays a vital role in maintaining the function of the cardiovascular, nervous, and central nervous systems.
Another frequently mentioned side effect associated with IGF-1 use is acromegaly, internal organ enlargement, and intestinal tissue growth.
High-dose or long-term continuous administration can induce the overgrowth of bone and soft tissues, with visible changes often appearing in areas like the jaw, hands, and feet.
This phenomenon rarely occurs within short, limited cycles and is typically caused by the long-term accumulation of excessive dosages. Once it develops, it is often irreversible.
Therefore, especially when using long-half-life variants like IGF-1 LR3, a single cycle should not exceed 30 days, followed by a sufficient off-period. This strategy is essential to prevent non-muscle tissue growth and abnormal distribution caused by IGF-1 receptor saturation.
Ultimately, excessive administration periods or high doses lead to the saturation of the body’s IGF-1 receptors. This causes excess IGF-1 to remain in the bloodstream, where it can bind to non-muscular tissues (bone, viscera, organs, etc.) and cause tissue enlargement. Over time, you will directly witness how this tissue growth leads to functional impairment or physical asymmetry.
IGF-1 Dosage, Administration, and Protocol
The recommended dosage for IGF-1 LR3 is 40-50 mcg per day for men and 20 mcg or less per day for women. Due to its long active half-life (approximately 20-30 hours), a single daily injection is sufficient to maintain physiological effects. Dosing more than once a day is not recommended as it can lead to receptor saturation and unnecessary spikes in concentration.
On training days, it is most common to administer IGF-1 LR3 either immediately pre-workout or post-workout, as this is when the sensitivity of IGF-1 receptors in muscle cells is maximized.
The choice between pre- or post-workout administration depends on personal preference and tolerance. If you choose to do both, the total daily dose should be split—for example, 20 mcg pre-workout and 20 mcg post-workout—ensuring the total daily amount does not exceed 40 mcg.
On rest days with no anaerobic or aerobic training, it is ideal to administer a single dose at a consistent time.
IGF-1 DES has a much shorter half-life (around 20-30 minutes) than IGF-1 LR3, thus requiring a relatively higher dosage to compensate for its brief physiological action. The typical daily dose ranges broadly from 50-150 mcg, with some high-intensity protocols utilizing over 200 mcg.
Due to its rapid absorption and ability to induce powerful cell growth signals, the DES variant is primarily used by elite bodybuilders via localized injections immediately post-workout.
Both IGF-1 LR3 and DES can be administered subcutaneously (SC) or intramuscularly (IM). However, even when aiming for localized muscle growth, achieving scientifically proven site-specific enhancement is difficult. Since it has been confirmed that the compound acts systemically, subcutaneous injection is often more efficient and carries a lower risk of pain and fibrosis than intramuscular injection.
An IGF-1 cycle should be limited to a maximum of 30 days, followed by a mandatory rest period of at least two weeks to allow for receptor recovery and restoration of homeostasis. In practice, Olympia-level prep cycles often adopt a protocol of 4 weeks on, followed by 4-6 weeks off.
Excessive dosages and continuous administration increase the risk of IGF-1 receptor desensitization and excessive growth in non-muscle tissues (organs, bones, nervous system, etc.). Therefore, periodic breaks to maintain receptor sensitivity and allow for systematic recovery are essential not only from a physiological standpoint but also for long-term health.
IGF-1 products are typically supplied as a lyophilized (freeze-dried) powder. For reconstitution, bacteriostatic water is used. For LR3 products in particular, using bacteriostatic water with 0.6% acetic acid is more stable and effective at maintaining the protein’s integrity after reconstitution.
The final concentration depends on the volume of diluent added by the user. Therefore, it is crucial to accurately calculate the dose per unit based on the total amount of powder (typically 1mg) and the volume of diluent (e.g., reconstituting with 2ml yields 50mcg per 10iu). This is considered an essential mathematical step for precise dosing of peptide agents.
In the protocols of internationally recognized chemical experts and former pro athletes like Dave Palumbo and John Meadows, a basic strategy involves using IGF-1 LR3 at 40 mcg/day for 30 days, followed by a 4-6 week off-period. For IGF-1 DES, the dosage is typically adjusted around 100 mcg/day while testing for injection site sensitivity and cellular growth response. Coaching strategies are designed to minimize the risks of acromegaly, visceral growth, and hypoglycemia associated with high doses and long-term use.
In conclusion, the safe and effective utilization of IGF-1 requires a solid understanding of cyclical usage strategies, timing based on half-life, the physiological response characteristics tied to its molecular structure, mathematical proficiency for reconstitution, and above all, the ability to keenly observe and adjust based on individual physiological feedback.
